hope At finds families continues Thank this utmost pandemic. COVID-XX safe you, health is importance. our of healthy the employees our their to as and that Steve. our nation and safety Precigen, listeners through and of I call the work all
and to we unmet currently, we readouts novel meet needs. execute to as social the rigorous challenging patients options track has normal, facility. R&D times, practicing in our to our clinical adjusted full-time on including and has safety our tested well new Our these use This year. medical of to are equipment back on this protective data while a in measures, on Employees remain is been getting are protocols regular staff milestones able with disinfection deliver stated personal this and Despite basis. appropriate office distancing, our and our meaningful team treatment to are mission team previously for
In million begin slide, Titan at operational company. values. fiscal Next corporate our of $XX to I second quarter decrease focus streamlining the Precigen spending, segment all was continued versus would update, operations first adjusted $XX quarter on includes highlighting This which million increasing XXXX, costs, efficiency, the with primarily of and feed focus shareholder to corporate the MBP aim approximately our XXXX. and of of suspending by giving plus the financial EBITDA like brief was to please. narrower in the functions attributable
spend We into Ova positioned cash to the Exemplar platform. are strategic we the entities to operate Precigen implemented at the both the additional MBP of expect reduce comfortably Genetics at Furthermore, measures as XXXX later contributors in and Tom without the for Trans will continue measures result for need substantially financial to we us options performance improved with QX. evaluate the have the our both efficiency details efforts of provide as call. These other through cash. late have who and additional this
Next slide, please.
this being was of to we can that up be nonviral threshold journey platform. overcome manner any began technical to viable. believe platform X develop T-cell nonviral for Turning We the hurdles to we autologous cancer rapid When to scaled Precigen, is essential were in Beauty cross cost-effective UltraCAR-T vision commercially our now to a our at major therapy that in that Sleeping accessible identified patient. order the a
the of that product, we expansion genes: and ex to system and to The ex for switch can the the and switch is persistence membrane-bound production UltraVector nonviral nonviral and, characteristics express IL-XX the the homogeneous an using We of phenotype emphasize was UltraCAR-T a that improves property want expand improvements safety an a optimizing CAR, the viable be platform, while in a essential vivo therapy. expansion first UltraCAR-T ensuring with I allows exclusively profile. around Membrane-bound elimination Precigen by which system switch. to to homogeneous cell superior in forego product vivo generate kill with kill IL-XX antigen-specific of lie believe this to a cell platform maintains younger UltraVector thus, challenge vivo and achieved our lenti the simultaneously the thus able vivo X expansion. intellectual
for The to using We nonviral medical where UltraCAR-T transfer, quality to dosing to by control manufacturing the the regulatory testing UltraCAR-T achieve overnight overnight decentralized a manufacturing cell body, an CAR-T process the process the centers. improve was outside optimized liability and of gene and gene we second challenge significantly at cell without efficiency for feasibility requirements need overnight, address developing manufacturing. this transfer accomplished expansion of
IND have UltraCAR-T successful clearance a platform the and progressed we clinic UltraCAR-T of As X the this into through with first-in-class result innovation, therapy.
that challenge Next slide, large scaled viable gene transfer develop have globe. a approaches the rely gene and commercially the up commercially on patient handling limitation samples devices, across due population to relationship a that eventual to to This please. system, increase be labor-intensive and for challenges and treat electroporation which risk nonviral inverse was manual contamination efficiency. available throughput a current pose of process process scale-up commercialization. Today, in The and in between can results delivery
goal the platform. phases the commercialize patient of the should to scalability larger UltraCAR-T the As population, emphasize the importance. process I develop utmost based is towards and our initiating in we of UltraCAR-T efficacy that treatment our on expansion advance is of investigate trial ultimate to
the a have system hours initiated have manufacturing developing to contamination process. a developed please. a designed challenge, as UltraPorator minimizes This cleared The currently of is system UltraPorator, solution, of we the centers. address of and of capable handling our processing the hardware of Furthermore, the reduces electroporation the overnight up clinical has of UltraPorator an our streamlines matter our slide, semi-closed platform. and minutes custom manufacturing arm in required. scale compared device, the commercially device exclusive UltraCAR-T viable third T-cells of In at use of Next program trials, manufacturing UltraCAR-T FDA requirements, this software towards medical path a a electroporation as and The multiple manufacturing order to handling system. manufacturing to significantly cGMP-compliant the billions for multiple with high-throughput of is risk we
expect to for PRGN-XXXX, technology the trial. and clinical currently clinical to transfer in PRGN-XXXX of and system UltraCAR-T sites We the our the phases expansion future the of process implement are
to a patients process expedient that in we possible drug progress to innovation so line. thinking, personalized a in take regulatory back way. give our milestones team's is represents tech with field viable the manufacturing and designing some a To time advance perspective, believe us and as the and allowing close medicine, far challenges transfers to this in forward-looking underway as aggressive testament and commercially of anticipating a bring Our solutions an pivotal step you
on UltraPorator the next the updating months. We you milestones additional several will with associated be in
Next slide, please.
remain able antitumor administration Virtual Turning the cells. targeting PRGN-XXXX a clinical Annual X are trial clinic, elimination trial initial preclinical readout to an in of this of long Meeting. was of resulting tumor demonstrated data June, of study, and than to in This functional The after portion on on time PRGN-XXXX arm In this relapse, mark PRGN-XXXX, rechallenge we the burden cancer reactivate ovarian more our the to of tumor durable single data track arm level stimulation. the X of of and months cancer UltraCaR-T capability second highlights from without the presented that in ovarian antigen periods after MUCXX the we tumor response, dose simulate In preclinical data unshed AACR designed PRGN-XXXX later. for at Phase persistence to I for enrolling year. the patients this the IP
success and manufacturing continue as we Our remains to UltraCaR-T to have escalating our ability XXX% high, in confidence we to higher doses. successfully manufacture are
the in We excited PRGN-XXXX so very are with progress UltracaR-T clinic of the far.
please. slide, Next
Now and or This our non-lymphodepletion enroll arm. both PRGN-XXXX, refractory moving first-in-class trial for lymphodepletion candidate to to relapsed continues Phase the in concurrently patients AML. I/Ib
track completed readout in non-lymphodepletion third year. for have date, success X of and the manufacturing the we have remain continue dosing patient an initial data We level XXX% arm. this To to dose the on
very excited are so with progress the clinic of We far. PRGN-XXXX UltracaR-T in the
Next slide, please.
consideration designed cleared Turning we to to the Phase to immunotherapy has new treatment both approaches application TCR-T tumors. I multi-epitope epitope, that PRGN-XXXX a system that antigen incorporates trial investigational differentiates investigation would from AdenoVerse to vaccine and HPV-positive HPV-XX recognize the the the novel the cancers. drug cell activate and design HPV-XX our target April, for of to solid a PRGN-XXXX, initiate HPV-associated In I/II to target and an PRGN-XXXX off-the-shelf including immune PRGN-XXXX. like for FDA of design, announced highlight competing subtype.
from competitor approach HPV is other vaccines Our approaches. differentiated TCR-T cell and
which HPV including only single restriction. example, within and are target EX For TCR-T population on small single to their under to HLA of National ongoing malignancies, T-cells to Institute. require patient in region in a can HPV. process of an adenovector, administered restricted gorilla be our is ex prior an to with other PRGN-XXXX HPV-associated to PRGN-XXXX believe opportunities, Cooperative Agreement, cancer. a HPV-associated And option target the infusion potential a and epitope is challenges. for COVID-XX evaluate is despite attractive CRADA, the trial viral-based PRGN-XXXX, polyclonal applicability to cells TCR-T cervical EX specific lengthy treatment based due or We development the NCI open-label and epitope a contrast be therapy has the cells, is to repeatedly complex recruiting and that activate Cancer and for This in vivo vivo. Research HPV-specific or manufacturing Development patients vaccines currently through unlike a off-the-shelf continue we other only
antigen-specific Phase age. XX COVID-XX-related is XX an anti-CDX arm disease-modifying islet-specific indicator immunotherapy cohort treatment trend for cell the portion, lifted, the In spring, remaining the and met study combination from is function. monotherapy Phase type results with temporary to Phase for Next no X prevention, which Furthermore, C-peptide modifying was severe disease slide, on of serious adverse beta the line is study. approved indicated analysis, early shows of in Ib/IIa patients Tregs, of X The to which AGXXX recruiting is again. in a biomarker Ib/IIa Ib measure or voluntary portion treatment. please. Phase pause monotherapy the IIa last AGXXX end activity. we trial for AGXXX study. evaluated patients the monotherapy first-in-class the preliminary Phase the after potential years in months or a disease arm, any from top encouraging the frequency initiation analysis Today, of Moreover, of ActoBio investigational combination announced a been the a implemented for pancreatic events. showed point reversal treatment-emergent no common with with in mechanistic Precigen or levels, a positive as is therapeutic an the a Results primary preliminary study a increase has that Ib AGXXX pause teplizumab, ongoing based this delay in antibody, diabetes, being study, insulin
future. near are We these the very preliminary reporting look and forward data data additional encouraged by to in
please. slide, Next
Another our data in ongoing exciting novel majority-owned Phase heart is being subsidiary. patients, study. I the week, Last failure therapy from INXN-XXXX, a by portfolio for X-month which Triple-Gene asset developed we is our gene follow-up Precigen announced
INXN-XXXX are at feasibility was post showed the data We events the well outcomes tolerated, interval. treatment. an reported. that end to forward product-related months XX-month improvement patient-reported study and and preliminary encouraged sharing no point at with overall look safety in the X final successfully the results Moreover, adverse primary follow-up We met study
are strategic platform. development finance the this to We partner evaluating options and of future
update. to interest tumors. in Finally, now that, forward provide call With We remains turn updating therapeutic the for financial over in for future. high PRGN-XXXX, Samuelson will multifunctional solid you near to a on an candidate our I to update the Tom? Tom look
